GlassScriptPhysician profile
Brent O Menninger
NPI 1952339053
$7,431.86
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,573 · 2020: $1,038 · 2021: $1,782 · 2022: $2,039.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,355.16 | 2019-2022 | |
| Lundbeck LLC | $642.45 | 2019-2022 | |
| Abbvie INC. | $587.98 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $581.48 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $568.09 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $558.00 | 2019-2022 | |
| Neos Therapeutics, LP | $442.32 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $437.05 | 2019-2022 | |
| Allergan, INC. | $271.12 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $205.28 | 2019-2020 | |
| Corium, LLC | $203.99 | 2022 | |
| Jazz Pharmaceuticals INC. | $192.45 | 2019-2021 | |
| Bausch Health US, LLC | $170.25 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $170.12 | 2019 | |
| Neurocrine Biosciences, INC. | $145.51 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $133.20 | 2021-2022 | |
| Neuronetics, INC. | $102.34 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $93.66 | 2021 | |
| Tris Pharma INC | $90.58 | 2019-2022 | |
| Shire North American Group INC | $82.09 | 2019 | |
| Avanir Pharmaceuticals, INC. | $80.87 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.21 | 2022 | |
| Axsome Therapeutics, INC. | $53.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $50.17 | 2019-2022 | |
| Adlon Therapeutics L.P. | $49.80 | 2021 | |
| Vertical Pharmaceuticals, LLC | $29.15 | 2019 | |
| Supernus Pharmaceuticals, INC. | $27.74 | 2022 | |
| Harmony Biosciences LLC | $20.99 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.11 | 2019 | |
| Indivior INC. | $14.05 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Menninger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.